Can I Take Calcium with Crestor (Rosuvastatin)?

The Short Answer: No Direct Interaction

Calcium and rosuvastatin do not appear to interfere with each other's absorption or metabolism in a clinically meaningful way. Rosuvastatin is taken up by the liver through organic anion transporter polypeptides OATP1B1 and OATP1B3, and its plasma half-life sits near 19 hours. Calcium does not inhibit or induce these transporters at dietary or supplemental doses.

Calling something "no direct interaction" is not the same as calling it zero-concern. Calcium does interact with several other drugs commonly prescribed alongside rosuvastatin, and sorting out your full medication-plus-supplement schedule matters more than any single two-drug pairing.

How Rosuvastatin Is Absorbed and Metabolized

Rosuvastatin is approximately 20% bioavailable after oral dosing, largely because of first-pass hepatic extraction. The liver handles most of the relevant pharmacology here: OATP1B1 and OATP1B3 pull the drug into hepatocytes, where it inhibits HMG-CoA reductase and cuts endogenous cholesterol synthesis by roughly 45-55% at the 10-20 mg dose range. CYP2C9 plays a minor metabolic role, and CYP3A4 (the enzyme that causes so many drug-drug interactions with other statins) is not meaningfully involved. [1]

This metabolic profile is why rosuvastatin has a relatively clean interaction profile compared to simvastatin or atorvastatin. Grapefruit juice, for example, does not affect rosuvastatin the way it affects simvastatin. Calcium, which does not touch CYP2C9 or hepatic OATP transporters, sits even further outside rosuvastatin's pharmacological orbit.

What Calcium Does in the GI Tract

Calcium carbonate and calcium citrate are the two dominant supplement forms. Calcium carbonate requires stomach acid for dissolution and is best absorbed with food. Calcium citrate dissolves without acid and can be taken fasted. Both forms bind to negatively charged molecules in the gut lumen, which is the mechanism behind calcium's well-documented interactions with levothyroxine, tetracycline antibiotics, fluoroquinolones, and bisphosphonates like alendronate. [2]

Rosuvastatin does not carry the surface charge profile that makes it vulnerable to calcium chelation. Its molecular structure does not invite the same lumenal binding.

Calcium's Real Interaction Risk: The Drugs Around Your Statin

Levothyroxine

Hypothyroidism and dyslipidemia travel together frequently. As many as 40% of hypothyroid patients have elevated LDL-C, which means levothyroxine and a statin often appear on the same prescription list. Calcium carbonate taken within two hours of levothyroxine reduces thyroid hormone bioavailability by up to 20-40% in controlled studies. A 1994 case series by Schneyer published in the Annals of Internal Medicine first documented this chelation effect in clinical patients, and subsequent pharmacokinetic work confirmed it. [3]

The practical fix is straightforward: take levothyroxine first thing in the morning, at least 30-60 minutes before any food, coffee, or supplements. Take calcium at lunch or dinner. Rosuvastatin can go at any consistent time.

Bisphosphonates

Alendronate (Fosamax) and risedronate (Actonel) are prescribed for osteoporosis prevention, a condition that often coexists with the post-menopausal population taking statins for cardiovascular risk. Calcium taken at the same time as an oral bisphosphonate essentially blocks the bisphosphonate from being absorbed. The FDA prescribing information for alendronate explicitly instructs patients to wait at least 30 minutes after bisphosphonate dosing before taking any food, drink, or other medication, including supplements. [4]

Calcium does not interfere with rosuvastatin in the same way. But if you are on alendronate plus rosuvastatin plus calcium, the sequencing of those three matters for the first two drugs, not for the third.

Antacids Containing Calcium

Some patients use calcium carbonate (Tums, Rolaids) as both a supplement and an antacid. Large antacid doses of aluminum/magnesium-based products reduce rosuvastatin AUC by approximately 54% when taken simultaneously, according to the Crestor prescribing information. Calcium-only antacids do not carry the same magnitude of effect, but the FDA label advises separating rosuvastatin from antacid combinations by at least two hours as a precaution. [5]

Does Supplemental Calcium Affect Cardiovascular Risk in Statin Users?

This question matters because rosuvastatin is itself a cardiovascular medication, and you want your supplement choices to support rather than undercut that goal.

The MESA Data and What It Actually Shows

The Multi-Ethnic Study of Atherosclerosis (MESA, N=5,448) found that dietary calcium intake correlated with lower coronary artery calcium (CAC) scores, but supplemental calcium was not associated with the same benefit and in some subgroup analyses was associated with higher CAC scores. The MESA calcium findings, published in the Journal of the American Heart Association in 2016, suggested the source of calcium (food vs. Pill) may matter for arterial calcification risk. [6]

This does not mean calcium supplements are dangerous for statin users specifically. Statins, including rosuvastatin, do not prevent arterial calcification; they reduce atherosclerotic plaque progression and cardiovascular events through LDL-lowering. A 2010 meta-analysis in the BMJ by Bolland et al. (N=12,000 pooled) found that calcium supplements without vitamin D were associated with a modest increase in MI risk (HR 1.27, 95% CI 1.01-1.59), though this finding remains debated because of study design limitations and baseline dietary calcium variation. [7]

The American Heart Association's current dietary guidance does not prohibit supplemental calcium but recommends meeting calcium needs through food sources when possible. [8]

Practical Cardiovascular Guidance for Rosuvastatin Patients

Keep supplemental calcium at or below the dose needed to meet your dietary gap. Most adults consuming dairy and fortified foods get 600-800 mg of calcium daily from diet alone. Supplementing 500 mg or less per day to close the gap carries a smaller potential signal than supplementing 1,000-1,200 mg on top of dietary intake.

Vitamin D co-supplementation modifies calcium absorption efficiency. The USPSTF found insufficient evidence in 2021 to recommend vitamin D and calcium supplementation for primary prevention of cardiovascular disease in community-dwelling adults, which shifted guidance away from high-dose combination supplementation. [9]

Timing Your Full Regimen: A Practical Schedule

No single timing schedule fits every patient, but the following framework accommodates the most common combinations seen in a statin-treated adult:

Morning (6-7 AM, fasted): Levothyroxine (if prescribed). Nothing else. Wait 30-60 minutes before anything else.

Morning (7-8 AM, with breakfast): Rosuvastatin (if your preference is morning dosing). Rosuvastatin is not significantly affected by food, so taking it with a meal is fine and may improve adherence.

With lunch or a midday snack: Calcium supplement (first dose if splitting). Taking calcium with food improves absorption for calcium carbonate specifically, and spreading doses across two or three smaller amounts (500 mg or less per dose) maximizes absorption efficiency because the active transport mechanism in the gut saturates at high single doses.

Evening (with dinner or at bedtime): Rosuvastatin (if evening dosing is preferred). Second calcium dose if splitting. Some clinicians prefer evening statin dosing because cholesterol synthesis follows a modest circadian rhythm, peaking at night, though this preference matters more for shorter-acting statins than for rosuvastatin's 19-hour half-life.

The key points:

• Calcium and rosuvastatin do not need to be separated from each other.
• Calcium and levothyroxine need at least a 2-hour gap (4-hour gap preferred by some endocrinologists).
• Calcium and oral bisphosphonates need at least a 30-minute separation, with the bisphosphonate taken first.

What the ACC/AHA Guidelines Say About Statin Monitoring

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "A fasting lipid panel should be obtained to assess the response to statin therapy 4 to 12 weeks after initiation and 4 to 12 weeks after any dose adjustment." [10]

Adding or changing a calcium supplement does not require a lipid recheck on its own, because calcium does not alter rosuvastatin's mechanism of action or its LDL-lowering effect. But if your most recent LDL-C is not meeting the guideline target (50% or greater reduction for high-risk patients, or LDL-C below 70 mg/dL for very-high-risk patients), your physician should review the full medication and supplement list for anything that might be limiting statin efficacy.

When to Call Your Prescriber

Contact your prescribing clinician in any of the following situations:

• Your LDL-C is not responding to rosuvastatin as expected and you have recently changed your supplement or antacid routine.
• You develop unexplained muscle pain, weakness, or dark urine (possible myopathy, unrelated to calcium but always worth reporting on any statin).
• You are starting a new medication (particularly cyclosporine, which increases rosuvastatin AUC by 7-fold, or gemfibrozil, which roughly doubles rosuvastatin exposure) and want to review all supplement timing. [11]
• You have chronic kidney disease (eGFR <30 mL/min/1.73m2), because calcium handling and cardiovascular calcification risk both change substantially in that population.

Rosuvastatin Efficacy: What the Trials Show

Understanding what rosuvastatin actually accomplishes helps you appreciate why getting the drug delivery right matters.

JUPITER Trial

The JUPITER trial (N=17,802) randomly assigned adults with LDL-C below 130 mg/dL but elevated high-sensitivity CRP to rosuvastatin 20 mg or placebo. Rosuvastatin reduced major cardiovascular events by 44% over a median 1.9 years of follow-up (HR 0.56, 95% CI 0.46-0.69, P<0.00001). The JUPITER results were published in the New England Journal of Medicine in 2008. [12]

ASTEROID Trial

The ASTEROID trial (N=507) used intravascular ultrasound to directly measure atherosclerosis regression. Rosuvastatin 40 mg daily over 24 months produced a median LDL-C reduction from 130.4 to 60.8 mg/dL and demonstrated statistically significant regression of coronary atherosclerosis for the first time with any statin. ASTEROID was published in JAMA in 2006. [13]

These trial outcomes depend on the drug actually reaching adequate plasma and hepatic concentrations. Anything that substantially reduces rosuvastatin bioavailability (high-dose aluminum/magnesium antacids taken simultaneously, or the cyclosporine interaction) threatens those outcomes. Calcium at typical supplemental doses does not.

Special Populations

Postmenopausal Women

This group is the most likely to be taking both rosuvastatin and calcium simultaneously. Cardiovascular disease becomes the leading cause of death in women after menopause, and bone loss accelerates in the same period. The coexistence of both indications is clinically common.

For postmenopausal women, the 2021 North American Menopause Society (NAMS) position statement on non-hormonal management supports calcium and vitamin D supplementation when dietary intake is inadequate, noting that evidence for fracture prevention is most consistent for women with low baseline calcium intake. [14] The NAMS statement does not identify statin use as a contraindication to calcium supplementation.

Patients with Hypercalcemia or Hypercalciuria

If you have a history of hypercalcemia, primary hyperparathyroidism, or calcium-containing kidney stones, your physician has likely already counseled you on limiting supplemental calcium. This is not a rosuvastatin-specific concern but a general calcium metabolism issue that applies regardless of statin use.

Older Adults (65+)

Absorption efficiency for calcium declines with age, which is why the National Institutes of Health Office of Dietary Supplements recommends 1,200 mg/day for women over 51 and men over 71. The NIH ODS calcium fact sheet provides full age- and sex-stratified recommendations. [15] Older adults also have higher baseline cardiovascular risk, making rosuvastatin adherence especially important. Keeping supplement schedules simple and writing down a consistent daily timing plan improves adherence in this age group.

Summary of Interaction Classification

Interaction databases classify drug-supplement interactions across several severity tiers. The Natural Medicines database (referenced by many pharmacists) rates the calcium-rosuvastatin interaction as having no interaction or a minor theoretical concern at most, based on the absence of clinical trial data demonstrating a meaningful pharmacokinetic effect.

By contrast, the calcium-levothyroxine interaction is rated moderate-to-major. The calcium-bisphosphonate interaction is rated major, with FDA label-level warnings. Clinicians should distinguish between these tiered risks rather than applying a blanket "separate everything" rule that reduces adherence.

The table below summarizes the relevant calcium interactions in a typical statin-using patient:

| Co-medication | Calcium Interaction Severity | Separation Needed | |---|---|---| | Rosuvastatin | None identified | Not required | | Levothyroxine | Moderate (chelation) | 2-4 hours | | Alendronate / risedronate | Major (absorption block) | 30+ minutes (bisphosphonate first) | | Aluminum/magnesium antacids | Moderate (when combined) | 2 hours | | Tetracycline antibiotics | Major | 2-3 hours | | Fluoroquinolone antibiotics | Major | 2 hours |